Protease-activated Receptors in Cancer: A Systematic Review

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Aug 1

PMID 22848234

Citations 23

Authors

Na Han

Ketao Jin

Kuifeng He

Jiang Cao

Lisong Teng

Affiliations

Soon will be listed here.

Abstract

The traditional view of the role of proteases in tumor growth, progression and metastasis has significantly changed. Apart from their contribution to cancer progression, it is evident that a subclass of proteases, such as thrombin, serves as signal molecules controlling cell functions through the protease-activated receptors (PARs). Among the four types of PAR (PAR1-4; cloned and named in order of their discovery), PAR1, PAR3 and PAR4 are activated by thrombin, unlike PAR2, which is activated by trypsin-like serine proteases. Thrombin has been proven to be a significant factor in both the behavior of cancer in its involvement in hemostasis and blood coagulation. Thrombin is a key supporter of various cellular effects relevant to tumor growth and metastasis, as well as a potent activator of angiogenesis, which is essential for the growth and development of all solid tumor types. This review presents an overview of the role of PAR-mediated thrombin in angiogenesis and cancer, focusing on the ability of PAR1- and PAR4-mediated thrombin to affect tumorigenesis and angiogenesis.

Citing Articles

PAR2 activation on human tubular epithelial cells engages converging signaling pathways to induce an inflammatory and fibrotic milieu.

Vesey D, Iyer A, Owen E, Kamato D, Johnson D, Gobe G Front Pharmacol. 2024; 15:1382094.

PMID: 39005931 PMC: 11239397. DOI: 10.3389/fphar.2024.1382094.

Cancer progression and tumor hypercoagulability: a platelet perspective.

Zhang Y, Zeng J, Bao S, Zhang B, Li X, Wang H J Thromb Thrombolysis. 2024; 57(6):959-972.

PMID: 38760535 DOI: 10.1007/s11239-024-02993-0.

Coagulation Protease-Driven Cancer Immune Evasion: Potential Targets for Cancer Immunotherapy.

Paul S, Mukherjee T, Das K Cancers (Basel). 2024; 16(8).

PMID: 38672649 PMC: 11048528. DOI: 10.3390/cancers16081568.

Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy.

Russo V, Falco L, Tessitore V, Mauriello A, Catapano D, Napolitano N Life (Basel). 2023; 13(9).

PMID: 37763292 PMC: 10532829. DOI: 10.3390/life13091888.

Thrombin cleavage of the hepatitis E virus polyprotein at multiple conserved locations is required for genome replication.

Pierce D, Buchanan F, Macrae F, Mills J, Cox A, Abualsaoud K PLoS Pathog. 2023; 19(7):e1011529.

PMID: 37478143 PMC: 10395923. DOI: 10.1371/journal.ppat.1011529.

References

Bromberg M, Bailly M, Konigsberg W . Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor. Thromb Haemost. 2002; 86(5):1210-4. View

Miyata S, Koshikawa N, Yasumitsu H, Miyazaki K . Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J Biol Chem. 2000; 275(7):4592-8. DOI: 10.1074/jbc.275.7.4592. View

Derian C, Damiano B, Addo M, Darrow A, DAndrea M, Nedelman M . Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003; 304(2):855-61. DOI: 10.1124/jpet.102.042663. View

Palumbo J, Degen J . Hemostatic factors in tumor biology. J Pediatr Hematol Oncol. 2000; 22(3):281-7. DOI: 10.1097/00043426-200005000-00019. View

Macfarlane S, Seatter M, Kanke T, HUNTER G, Plevin R . Proteinase-activated receptors. Pharmacol Rev. 2001; 53(2):245-82. View

Stenberg P, McEver R, Shuman M, Jacques Y, BAINTON D . A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985; 101(3):880-6. PMC: 2113718. DOI: 10.1083/jcb.101.3.880. View

Oikonomopoulou K, Hansen K, Saifeddine M, Vergnolle N, Tea I, Diamandis E . Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. Biol Chem. 2006; 387(6):677-85. DOI: 10.1515/BC.2006.086. View

Marutsuka K, Hatakeyama K, Sato Y, Yamashita A, Sumiyoshi A, Asada Y . Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res. 2002; 107(5):271-6. DOI: 10.1016/s0049-3848(02)00345-6. View

Covic L, Misra M, Badar J, Singh C, Kuliopulos A . Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002; 8(10):1161-5. DOI: 10.1038/nm760. View

10.

Teng L, Jin K, He K, Zhang J, Wang H, Cao J . Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010; 73(9):449-56. DOI: 10.1016/S1726-4901(10)70097-6. View

11.

Fischer E, Riewald M, Huang H, Miyagi Y, Kubota Y, Mueller B . Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest. 1999; 104(9):1213-21. PMC: 409824. DOI: 10.1172/JCI7750. View

12.

Faruqi T, Weiss E, Shapiro M, Huang W, Coughlin S . Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem. 2000; 275(26):19728-34. DOI: 10.1074/jbc.M909960199. View

13.

Kuliopulos A, Covic L . Blocking receptors on the inside: pepducin-based intervention of PAR signaling and thrombosis. Life Sci. 2003; 74(2-3):255-62. DOI: 10.1016/j.lfs.2003.09.012. View

14.

Kahn M, Shapiro M, Ishihara H, Coughlin S . Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999; 103(6):879-87. PMC: 408153. DOI: 10.1172/JCI6042. View

15.

Andrade-Gordon P, Maryanoff B, Derian C, Zhang H, Addo M, Darrow A . Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A. 1999; 96(22):12257-62. PMC: 22903. DOI: 10.1073/pnas.96.22.12257. View

16.

Hirsh J . Current anticoagulant therapy--unmet clinical needs. Thromb Res. 2003; 109 Suppl 1:S1-8. DOI: 10.1016/s0049-3848(03)00250-0. View

17.

Nantermet P, Barrow J, Lundell G, Pellicore J, Rittle K, Young M . Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1). Bioorg Med Chem Lett. 2002; 12(3):319-23. DOI: 10.1016/s0960-894x(01)00745-4. View

18.

Resendiz J, Kroll M, Lassila R . Protease-activated receptor-induced Akt activation--regulation and possible function. J Thromb Haemost. 2007; 5(12):2484-93. DOI: 10.1111/j.1538-7836.2007.02769.x. View

19.

Vu T, Hung D, Wheaton V, Coughlin S . Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991; 64(6):1057-68. DOI: 10.1016/0092-8674(91)90261-v. View

20.

Wojtukiewicz M, Tang D, Nelson K, Walz D, Diglio C, Honn K . Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res. 1992; 68(3):233-45. DOI: 10.1016/0049-3848(92)90081-k. View